COMPANY NEWS
MedTech start-up, Axis Spine Technologies, completes £2.2m funding round led by ACF Investors
Axis Spine Technologies Ltd (AST) has raised £2.2m in a funding round led by ACF Investors, with follow-on investment from Mercia’s EIS funds. Mercia was the first investor when Axis
Sacrix develops new iteration of SacroFuse for sacroiliac joint support
Sacrix has developed the third iteration of the SacroFuse threaded compression device for immediate stabilisation of the sacroiliac joint for pain relief and ultimately fusion
RABEA by SIGNUS – gold standard in anterior cervical fusion
Promotional feature RABEA® SIGNUS developed the first plan-parallel fusion cage worldwide. RABEA® received CE approval in 1996 and is, more than 25 years later, still gold standard in anterior
ST-Line – Next in fusion
Promotional feature With its new ST-Line, SIGNUS has applied the progress from endoprosthetic research to spinal surgery Regardless of the application, the excellent mechanical and biological properties of titanium and
Success of first JASPIS ST® surgery in Australia
Neurosurgeon Dr Andrew Miles, Neurospine Institute, Western Australia successfully completed the first JASPIS® ST surgery in Australia. Dr Miles’ first JASPIS ST case was a patient with degenerative disc disease
More appealing, more informative and with new functions: the revised SIGNUS website is online
Since the end of August SIGNUS presents itself with a new website. The new online presence offers clearly arranged and comprehensive information about the family business SIGNUS, its products and
Results of the largest independent randomised controlled trial of a digital therapy against chronic pain
In the largest independent randomised controlled trial (RCT) of its type, a multimodal app-based digital therapy programme for patients with non-specific low back pain has outperformed standard-of-care treatment across all
Biocomposites signs new exclusive distributor in Australia
Biocomposites, an international medical devices company that engineers, manufactures and markets products for use in infection management in bone and soft tissue, recently announced that it has signed an exclusive
DePuy Synthes extends partnership with AO
DePuy Synthes will continue to work with the AO Foundation to deliver professional education and develop innovations that help improve patient outcomes and increase efficiency of care, after renewing their
